Letters to the Editor

Blinatumomab for measurable residual disease relapse in acute myeloid leukemia with t(8;21) translocation: the BlinAML Trial

Department of Medical and Molecular Genetics, King’s College, London
Department of Medical and Molecular Genetics, King’s College, London, UK; Department of Clinical Haematology, Guy’s Hospital, London, UK; Faculty of Medicine and Health, The University of Sydney, Sydney
Department of Medical and Molecular Genetics, King’s College, London
Department of Medical and Molecular Genetics, King’s College, London
Department of Medical and Molecular Genetics, King’s College, London
Department of Medical and Molecular Genetics, King’s College, London
Department of Clinical Haematology, Guy’s Hospital, London
Department of Clinical Haematology, Guy’s Hospital, London
Department of Clinical Haematology, Guy’s Hospital, London
Department of Medical and Molecular Genetics, King’s College, London, UK; Department of Clinical Haematology, Guy’s Hospital, London
Department of Clinical Haematology, Guy’s Hospital, London
Department of Medical and Molecular Genetics, King’s College, London, UK; Department of Clinical Haematology, Guy’s Hospital, London
Department of Medical and Molecular Genetics, King’s College, London, UK; Department of Clinical Haematology, Guy’s Hospital, London
Haematologica Early view Jul 23, 2026 https://doi.org/10.3324/haematol.2026.301120